A study examining the impact of inactivating Ezh2 mutations in myeloid malignancies in mice reported that mice developed myelodysplastic disorders that were transplantable and led to the development of myelodysplastic syndrome (MDS), lymphoma, and lymphoproliferative disease (Mochizuki-Kashio et al., 2015). This evidence concerns the gene EZH2 and myelodysplastic syndrome.